Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVJoel E. Gallant, Andrew Cheng, Edwin DeJesus et al.|New England Journal of Medicine|2006Cited by 886
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Nathan Clumeck et al.|The Lancet Infectious Diseases|2011Cited by 172
Additional molecular testing of saliva specimens improves the detection of respiratory virusesKelvin Kai‐Wang To, Kwok‐Yung Yuen, Lu Lu et al.|Emerging Microbes & Infections|2017Cited by 151
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Daniel S Berger et al.|The Journal of Infectious Diseases|2010Cited by 114
Evaluation of the commercially available LightMix® Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detectionCyril Chik‐Yan Yip, Jasper Fuk‐Woo Chan, Siddharth Sridhar et al.|Journal of Clinical Virology|2020Cited by 57